Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Pfizer
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00039910CT.gov Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | — | Completed | — | — | — |
NCT00037791CT.gov Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thrombocytopenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| /Pn-196,444 (this asset) | Pfizer | P3 | BB · 66 |
| Recombinant Human Thrombopoietin | Sun Yat-sen University | P4 | BBB |
| Eltrombopag | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
| Avatrombopag | Second Affiliated Hospital of Guangzhou Medical University | P4 | BB |
| Nivestim | OHSU Knight Cancer Institute | P2 | BB |
| Hetrombopag | Sun Yat-sen University | P3 | BB |
| Cytarabine | OHSU Knight Cancer Institute | P2 | BB |
| Cyclosporin A | Children's Hospital Los Angeles | P2 | BB |
| Fludarabine | University of Utah | P2 | BB |
+42 more in the Thrombocytopenia cohort
Other indications for /Pn-196,444
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P3 | BB · 64 |
| Hodgkins Lymphoma | — | P3 | B · 62 |
| Non-Hodgkin Lymphoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. /Pn-196,444 in Thrombocytopenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pn-196444-thrombocytopenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →